Address: Pascalstraße 6
52076 Aachen-Oberforstbach
Germany
Tel: 0.000357327771660262
Web: http://www.grunenthal.de/grt-web/Grunenthal_GmbH_Deutschland/136701132.jsp
Grünenthal is passionate about globally being the preferred partner in pain management for patients, health-care-professionals and payors. The corporation drives innovation to expand European market leadership in moderate to severe pain. Grünenthal is an independent, family-owned German corporation with companies in 34 countries all over the world. Founded in 1946, the corporation employs 2,000 people in Germany and 5,200 worldwide. In 2008, Grünenthal achieved revenues of about 864 million Euros.
Together with highly specialised partners we are pressing on with the research and development of new active substances. For this we are concentrating on selected indications and the latest technological developments. We are intensively searching for innovative ways of improving pain, pain relief and reducing side-effects.
Grünenthal is an independent, family-owned, research-based pharmaceutical company based in Aachen operating internationally. In 1948 Grünenthal was the first German company to manufacture and market penicillin. Today analgesics are our main competence. Beside this Grünenthal is active in the marketing of oral contraceptives and the treatment of respiratory tract diseases.
Oskar Möbert, vice president of Veeva OpenData, discusses how standardizing customer reference data and systems organization-wide can help biopharmas scale globally and become more agile in their business. Data…
The biggest pharma industry and healthcare stories from Germany, including the country’s legalisation of cannabis; the MASH potential of Boehringer Ingelheim’s obesity candidate; Bayer’s further share price drop and expansion…
Pharma is rushing to adopt AI-driven tools in the hope of revolutionizing everything from drug discovery to clinical trials, regulatory submissions, and marketing efforts. While AI is the technology du…
Susanne Schaffert’s over 20-year stint at Novartis culminated with her presidency of the Swiss giant’s global oncology division, but when the company underwent a major restructure in 2022, she found…
As head of digital transformation at Bayer, Saskia Steinacker is well placed to unpack the hype around artificial intelligence in healthcare. In a wide-ranging interview, she explains how AI is…
Rainer Westermann of venture capitalist coalition Life Sciences Acceleration Alliance reviews the potential impact of the EU’s general pharmaceutical legislation on the investment climate for the EU life sciences sector.…
The latest pharma industry news from Germany, including Lilly’s new German plant; Bayer’s aborted anti-clotting drug trial and legal worries; Boehringer Ingelheim’s acquisition of Swiss biotech T3 Pharmaceuticals, and Hermes…
After positions at Novartis and Merck, Bettina Bauer, a trained scientist, joined Gilead in 2019 as VP and general manager of its German affiliate. Today, as the VP of the…
Merck’s Kaushal Kishore attempts to illustrate why pharma companies have struggled to crack what he calls “the Gross to Net (GtN) code.” He outlines the maturity journey for a pharma…
Patents can be an excellent way to demonstrate value, not only showing that a technology is protected but also how promising it can be when it eventually comes to market.…
The rise of niche therapies is shaping a more tailored engagement model, driven by data and AI, writes Florian Schnappauf, vice president of enterprise commercial strategy at Veeva Europe. …
Following the COVID-19 pandemic and the resulting supply chain disruptions, global drug pricing and access reforms have multiplied. The Inflation Reduction Act (IRA) has been introduced in the US while…
See our Cookie Privacy Policy Here
